While neither medication is FDA-approved for combined use, some healthcare providers may consider this pairing in select cases
The SUSTAIN 10 trial demonstrated a 1.7% reduction at week 30
Results The metabolic rate of GLP-1R KO mice was significantly slower than that of WT mice ( p = 0.0345, WT mice 0.02335 0.057 mM/min, GLP-1R KO mice 0.01998 0.07 mM/min)
5 Protein is the highest-priority category because 20-40% of weight loss on GLP-1 medications comes from lean muscle mass, creating genuine clinical demand alongside behavioral preference
While natural approaches can effectively support GLP-1 function for many people, pharmaceutical GLP-1 receptor agonists may be appropriate in certain clinical situations
The ideal scenario: use tirzepatide to reach a healthier weight, stop the medication with adequate washout time, conceive at a lower BMI, and benefit from improved metabolic health throughout the pregnancy